摘要
European Journal of NeurologyVolume 29, Issue 7 p. 1867-1868 COMMENTARY Biomarker development in amyotrophic lateral sclerosis: Challenges and viable strategies Peter Bede, Corresponding Author Peter Bede [email protected] orcid.org/0000-0003-0492-4772 Computational Neuroimaging Group, Trinity College Dublin, Dublin, Ireland Department of Neurology, St James's Hospital, Dublin, Ireland Correspondence Peter Bede, Computational Neuroimaging Group, Trinity College Dublin, Dublin, Ireland. Email: [email protected] Contribution: Conceptualization (equal), Writing - original draft (equal)Search for more papers by this authorJasmin Lope, Jasmin Lope Computational Neuroimaging Group, Trinity College Dublin, Dublin, Ireland Contribution: Conceptualization (equal), Writing - original draft (equal)Search for more papers by this author Peter Bede, Corresponding Author Peter Bede [email protected] orcid.org/0000-0003-0492-4772 Computational Neuroimaging Group, Trinity College Dublin, Dublin, Ireland Department of Neurology, St James's Hospital, Dublin, Ireland Correspondence Peter Bede, Computational Neuroimaging Group, Trinity College Dublin, Dublin, Ireland. Email: [email protected] Contribution: Conceptualization (equal), Writing - original draft (equal)Search for more papers by this authorJasmin Lope, Jasmin Lope Computational Neuroimaging Group, Trinity College Dublin, Dublin, Ireland Contribution: Conceptualization (equal), Writing - original draft (equal)Search for more papers by this author First published: 25 April 2022 https://doi.org/10.1111/ene.15372Citations: 2 See paper by Y. M. Falzone et al. on page 1930 Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Burke T, Pinto-Grau M, Lonergan K, et al. Measurement of social cognition in amyotrophic lateral sclerosis: a population based study. PLoS One. 2016; 11(8):e0160850. 2Querin G, Bede P, El Mendili MM, et al. Presymptomatic spinal cord pathology in c9orf72 mutation carriers: a longitudinal neuroimaging study. Ann Neurol. 2019; 86(2): 158-167. 3Blasco H, Patin F, Descat A, et al. A pharmaco-metabolomics approach in a clinical trial of ALS: identification of predictive markers of progression. PLoS One. 2018; 13(6):e0198116. 4Falzone YM, Domi T, Mandelli A, et al. Integrated evaluation of a panel of neurochemical biomarkers to optimize diagnosis and prognosis in amyotrophic lateral sclerosis. Eur J Neurol. 2022; 29(7): 1930-1939. doi:https://doi.org/10.1111/ene.15321 5Abidi M, de Marco G, Couillandre A, et al. Adaptive functional reorganization in amyotrophic lateral sclerosis: coexisting degenerative and compensatory changes. Eur J Neurol. 2020; 27(1): 121-128. 6Bede P, Chipika RH, Finegan E, et al. Brainstem pathology in amyotrophic lateral sclerosis and primary lateral sclerosis: a longitudinal neuroimaging study. Neuroimage Clin. 2019; 24: 102054. 7Finegan E, Chipika RH, Li Hi Shing S, et al. The clinical and radiological profile of primary lateral sclerosis: a population-based study. J Neurol. 2019; 266(11): 2718-2733. 8El Mendili MM, Querin G, Bede P, Pradat PF. Spinal cord imaging in amyotrophic lateral sclerosis: historical concepts-novel techniques. Front Neurol. 2019; 10: 350. 9Christidi F, Karavasilis E, Rentzos M, et al. Hippocampal pathology in amyotrophic lateral sclerosis: selective vulnerability of subfields and their associated projections. Neurobiol Aging. 2019; 84: 178-188. Citing Literature Volume29, Issue7July 2022Pages 1867-1868 ReferencesRelatedInformation